

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
02 August 2018 (02.08.2018)



(10) International Publication Number
WO 2018/140907 A1

(51) International Patent Classification:

A61K 31/439 (2006.01) C07D 211/74 (2006.01)

A61K 31/45 (2006.01)

(21) International Application Number:

PCT/US2018/015826

(22) International Filing Date:

30 January 2018 (30.01.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/451,920 30 January 2017 (30.01.2017) US

(71) Applicant: UP THERAPEUTICS INC. [US/US]; 6811
Old Waterloo Road, Suite 916, Elkridge, MD 21075 (US).

(72) Inventor: CHANG, Yung-Nien; c/o Up Therapeutics Inc.,
6811 Old Waterloo Road, Suite 916, Elkridge, MD 21075
(US).

(74) Agent: MCGOWAN, Malcolm K. et al.; Cermak Naka-
jima & McGowan LLP, 127 S. Peyton Street, Suite 200,
Alexandria, VA 22314 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: NOVEL SPIRO AND CYCLIC BIS-BENZYLIDINE PROTEASOME INHIBITOR FOR THE TREATMENT OF CAN-
CER, DIABETES AND NEUROLOGICAL DISORDERS

(57) Abstract: Described herein are spiro and cyclic bis-benzylidene proteasome inhibitors, which inhibit the proteasome function
through either ubiquitin receptor ADRM1/RPN13 or proteasome DUB enzymes (USP14, UCH37 and RPN11), and which can be used
for the treatment of cancers/diabetes/neurological disorders.

WO 2018/140907 A1